MICROCHIP TECHNOLOGY INCORPORATED (MCHP): what the price assumes

In the published model solve dated 2026-Q2, anchored at $73.08, MICROCHIP TECHNOLOGY INCORPORATED (MCHP) is priced for today's economics sustained for ~17.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-03.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/MCHP

Headline

FieldValue
TickerMCHP
CompanyMICROCHIP TECHNOLOGY INCORPORATED
Current price$73.08/sh
CompositionMixed-signal Microcontrollers 50% / Analog 28% / Other 22%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)50.0%
Operating margin today15.5%
Margin expansion (value-band)+34.5pp
Must persist for17.4y
Multiple paid54x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 12.3% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: elevated (limited comparison data)

ReferenceValue
vs own history+0.06σ
cohort percentile (of 188 peers)87

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset8.14x4expensive
Earnings5.76x5expensive
Relative5.91x2expensive
Growth0.83x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$87.750.83xyesFCF base $1.3B, growth 22% (input: historical growth), terminal g 4.0%, WACC 8.2%, 7yr projection
DCF Exit MultipleGrowth$94.410.77xyesExit EV/EBITDA: 28.5x / 30.5x / 32.5x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelativenoP/E 40.28x (blended: static sector reference 22x + trailing (TTM) 83x), scenarios: 32.6x / 40.3x / 48.0x (bear / base = reference held flat / bull), EV/EBITDA 20.35x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$9.527.68xyesBV/sh $11.88, ROE (TTM) 7.4%, ke 9.3%
Two-Stage Excess ReturnAsset$8.498.61xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$85.600.85xyesRev $5.1B, growth 22% (input: historical growth; tapered), Terminal P/S: 6.3x / 7.7x / 9.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$8.168.96xyesEPS $0.68, growth 2% (input: historical EPS growth), PEG=43.18 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$19.943.66xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.66B × (1−21%) / WACC 8.2% → EPV (no growth)
Residual IncomeAsset$8.348.76xyesBV $11.88 + 5yr PV of (ROE (TTM) 7.4% − Kₑ 9.3%) × BV; BV grows 4.8%/yr
Graham NumberAsset$13.485.42xyes√(22.5 × EPS $0.68 × BVPS $11.88) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $1.47B × sector EV/EBITDA 16.0x
FCF YieldEarnings$12.685.76xyesFCF $1110.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$7.1510.22xyesSBC-adj FCF $0.83B (FCF $1.11B − SBC $0.28B) capitalized at Kₑ
Ben Graham FormulaEarnings$21.943.33xyesEPS $0.68 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$3.3321.95xyesBV $11.88 × (ROIC 2.3% / WACC 8.2%) (excluded from median)
P/Sales SectorRelativenoRevenue $5.12B × sector P/S 5.0x
PEG Fair ValueRelative$25.502.87xyesEPS $0.68 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$7.359.94xyesEPS $0.68 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Semiconductor productsoperatingenterprise$4.5bwithheldunresolved no unit value
Technology licensingoperatingenterprise$163.8mwithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$5.1b
Net debt / NOPAT (after-tax)8.08x
Net debt / operating income (pre-tax)6.40x
Interest coverage3.7x
Share count CAGR (buyback)-0.5%
Burning cashno

Bullet Takeaways

Microchip is a moat-rich embedded-control franchise coming out of a deep cyclical trough. Gross margin has recovered to 61.6% from a 52% bottom, and management declared the inventory correction complete with the largest booking month in nearly four years.

The price prices the recovery aggressively. At $99.71 (as of June 27, 2026) no valuation family reaches the price, and the embedded margin assumption is far above what the company earns today, so the buyer is paying for a full normalization.

The balance sheet is the constraint on patience. Net debt of about $5.26 billion against still-recovering earnings means coverage is tight near the trough, and management is prioritizing debt reduction over other uses of cash.

Bull Case

Microchip's competitive moat is the foundation of the thesis, and it is built on switching costs that compound over decades. The company develops "smart, connected and secure embedded control solutions," with a portfolio spanning "general purpose and specialized 8-bit, 16-bit, and 32-bit mixed-signal microcontroller" products plus analog and the surrounding software and tools (FY2025 10-K, accession 0000827054-25-000077). Once a microcontroller is designed into a product, replacing it means re-engineering the customer's hardware and firmware, so designs stick for the life of the end product, often many years. That stickiness is why Microchip earns high through-cycle margins and why a downturn is a pause, not a permanent loss. The franchise is concentrated in microcontrollers (50% of revenue) and analog (28%), the two highest-quality, longest-lived semiconductor categories.

The cyclical recovery is now visibly underway, and the operating leverage is powerful. Fiscal Q4 2026 revenue rose 35.1% year over year to $1.311 billion, topping guidance, and non-GAAP gross margin recovered to 61.6% from a 52% trough a year earlier as the nine-point recovery plan took hold. Management declared the inventory correction complete, with days of inventory falling to 185 from a peak of 266, and reported that April was the largest booking month in nearly four years. The recovery is broad-based across end markets, led by aerospace and defense and data center, and full-year non-GAAP net income rose 31.8% to $933.9 million.

The growth optionality and the capital-return record sweeten the recovery story. The Data Center Solutions business is scaling from about $303 million in revenue toward roughly $500 million, winning PCIe Gen6 switch designs and entering the retimer market aimed at AI infrastructure, a genuine new growth vector layered on the core franchise. Microchip has paid a dividend for 94 consecutive quarters, a discipline it maintained through the trough while prioritizing debt reduction, and the share count is shrinking modestly. A moat-rich embedded-control leader emerging from an inventory correction with gross margin already back above 61%, broad-based bookings recovery, and an AI-driven data-center kicker is the kind of franchise where the cyclical low is the opportunity.

Bear Case

The structural problem sits on the right side of the balance sheet: Microchip carries net debt of about $5.26 billion, and it took on that leverage before a brutal downcycle hollowed out its earnings. At the trough, interest coverage compressed to roughly 5 times and net debt ran above 5 times operating income, a precarious ratio for a cyclical semiconductor company. The 10-K notes that the senior-note indentures carry "customary affirmative and negative covenants, including covenants that limit or restrict the Company and its subsidiaries' ability to" take various actions (FY2025 10-K, accession 0000827054-25-000077), so the debt is not just a number, it constrains flexibility. Management is explicitly prioritizing debt reduction over buybacks, which tells you the balance sheet is the binding concern, not an afterthought.

The valuation prices a recovery that is far from fully earned. At $99.71, no valuation family reaches the price: the stock is rich on assets, earnings power, peer multiples, and even forward growth, with the blended X-ray figure near $20.39, a fraction of the price. The priced-in characterization is that the price is a bet beyond what any standard frame supports, with an implied operating margin around 77% and an implied duration of more than 19 years, figures that are only possible because today's trough margin of 10.4% is so depressed that the model must assume an extreme and prolonged normalization to reach the price. In plain terms, the market has already priced a complete, durable cyclical recovery, leaving no cushion if the upturn stalls.

The cyclicality cuts both ways, and the recovery's durability is unproven. The same inventory dynamics that crushed earnings can recur: the correction that just ended was severe, and semiconductor demand is notoriously prone to double-dips. Fab restructuring, including a Fab 2 closure with special charges, shows the company is still resizing its manufacturing footprint, and capacity underutilization charges decline only modestly as fabs ramp over a multi-year period. A company servicing $5.26 billion of net debt, with a price that assumes a near-perfect long-term margin recovery and a balance sheet that constrains its options, is exposed on two fronts at once: if the recovery slows, both the earnings and the ability to delever weaken together, and the price sits far above every method that values the business as it actually is today.

Valuation

Microchip trades above every conventional valuation frame, and the X-ray says so bluntly. Against the $99.71 price, no family reaches the price: it is rich on assets, earnings power, peers, and even forward growth, with the blended figure across six methods near $20.39, far below the quote. The priced-in characterization is that the price is a bet beyond what any standard frame supports. This is a deep-cyclical valuation: the price is anchored to a normalized future, not to the depressed present.

The priced-in math is extreme precisely because the current earnings are at a trough. The model holds a current operating margin of 10.4% but must assume an implied margin around 77% over an implied duration above 19 years to justify the price. Those numbers are not a forecast of 77% margins; they are the mathematical consequence of trying to support today's price off a trough earnings base. The more useful anchor is the mid-cycle operating margin of 23.8% the company has demonstrated historically: the price requires not just a return to that mid-cycle level but sustained growth well beyond it. The gross-margin recovery to 61.6% is real progress toward normalization, but the price assumes the normalization is complete and durable.

The balance sheet is the constraint the valuation underweights. Net debt of about $5.26 billion sits at roughly 4.7 times operating income on a mid-cycle basis and higher on trough earnings, with interest coverage near 5 times, and the indenture covenants limit flexibility (FY2025 10-K, accession 0000827054-25-000077). An investor here is underwriting that the embedded-control moat drives margins back toward and beyond mid-cycle, that the data-center growth vector materializes, and that the company delevers along the way, all of which the price already assumes is delivered.

Catalysts

Fiscal Q4 2026 results (ended March 31, 2026, reported May 2026) confirmed the cyclical turn. Revenue rose 35.1% year over year to $1.311 billion, above the high end of guidance, non-GAAP diluted EPS was $0.57, and non-GAAP gross margin recovered to 61.6% from a 52% trough. Management declared the inventory correction complete, with days of inventory down to 185 from a peak of 266, and called April the largest booking month in nearly four years. The pace of gross-margin recovery and the durability of bookings are the key near-term catalysts, and forward guidance pointed to continued sequential and year-over-year growth.

The data-center growth vector is the strategic catalyst. The Data Center Solutions business is scaling from about $303 million toward roughly $500 million in 2026, with six PCIe Gen6 switch design wins and a new entry into the retimer market aimed at AI infrastructure. Adoption of these products and their contribution to the mix is a potential upside catalyst that would diversify Microchip beyond its traditional cyclical end markets.

Deleveraging and capital allocation are the structural watch items. Management is prioritizing debt reduction, with operating cash flow resuming coverage of debt and the dividend, and the company maintained its 94-consecutive-quarter dividend record. Fab restructuring, including a Fab 2 closure with special charges, continues to resize the manufacturing footprint as underutilization charges decline gradually. Shares have run up sharply year to date on AI-driven demand and the recovery, so analyst views are mixed on valuation. The catalysts that would justify the price are sustained margin normalization toward mid-cycle and beyond, data-center growth, and visible debt reduction; the risk is a stalled recovery colliding with the leverage.

Peer Cohorts (Per Segment, With Filing Citations)

Semiconductor products (reported)

Technology licensing (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MCHP report on boothcheck